Can P-glycoprotein influence the bioavailability of iminosugar-based glucosylceramide synthase inhibitors?
Recently developed glucosylceramide synthase inhibitors with enhanced hydrophobicity display increased bioavailability in the central nervous system (CNS). Have these improvements come at a potential risk given that the improved glucosylceramide synthase inhibitors bear the hallmarks of P-glycoprote...
Main Authors: | Norris-Cervetto, E, Butters, T, Martin, C, Modok, S, Dwek, R, Callaghan, R |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2006
|
Similar Items
-
Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells.
by: Norris-Cervetto, E, et al.
Published: (2004) -
Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease
by: Boucheron, C, et al.
Published: (2005) -
Design and synthesis of iminosugar-based inhibitors of glucosylceramide synthase: the search for new therapeutic agents against Gaucher disease (vol 16, pg 1747, 2005)
by: Boucheron, C, et al.
Published: (2005) -
Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses
by: Butters, T, et al.
Published: (2005) -
Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
by: Karen M Ashe, et al.
Published: (2011-01-01)